ImmPACT Raises $110m As Bispecific CAR-T Shows Promising Response Rates

Next-Gen Cell Therapy Firm Aims To Solve First-Gen Problems

 
• By Mandy Jackson

ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment. 

Blue background with wooden gears. Mind works and new ideas concept.
ImmPACT raised $111m to advance its three big ideas for improving CAR-T therapies • Source: Alamy

More from Financing

More from Business